bioMérieux S.A. (EPA: BIM)

Market Cap	11.51B
Revenue (ttm)	3.81B
Net Income (ttm)	411.30M
Shares Out	118.01M
EPS (ttm)	3.47
PE Ratio	28.10
Forward PE	22.25
Dividend	0.85 (0.87%)
Ex-Dividend Date	Jun 7, 2024

Volume	132,917
Open	97.85
Previous Close	97.75
Day's Range	97.25 - 98.35
52-Week Range	88.25 - 111.50
Beta	0.19
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 25, 2024

About bioMérieux

bioMérieux S.A. develops and markets in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers CHROMID RANGE, a chromogen culture media; RAPIDEC CARBA NP biochemical test for the detection of carbapenemaseproducing bacteria; air, surface, and water monitoring systems; BACT/ALERT VIRTUO BACT/ALERT 3D, a blood sample culture system; BIOFIRE, a multiplex polymerase chain reaction (PCR) system; BIOFIRE SPOTFIRE Lowplex PCR point-of-care system; V...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 1963
• Employees: 13,982
• Stock Exchange: Euronext Paris
• Ticker Symbol: BIM

Financial Performance

In 2023, bioMérieux's revenue was 3.67 billion, an increase of 2.38% compared to the previous year's 3.59 billion. Earnings were 357.60 million, a decrease of -20.95%.